Evidence map›Paper›PMID 40660181›Full record

ArticleBMC cancer2025

Gene expression in tumor and adjacent normal tissues in lung adenocarcinoma subtypes.

Olga Y Gorlova, Ivan P Gorlov, R Taylor Ripley, Chao Cheng, Yafang Li, Bo Peng, Yanhong Liu, Hee-Jin Jang, Sung Wook Kang, Claire Lee and 4 more

Abstract read
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Olga Y Gorlova *Baylor College of Medicine, Houston, USA.
Ivan P Gorlov *Baylor College of Medicine, Houston, USA. ivan.gorlov@bcm.edu.
R Taylor RipleyBaylor College of Medicine, Houston, USA.
Chao ChengBaylor College of Medicine, Houston, USA.
Yafang LiUniversity of New Mexico, Albuquerque, USA.
Bo PengBaylor College of Medicine, Houston, USA.
Yanhong LiuBaylor College of Medicine, Houston, USA.
Hee-Jin JangBaylor College of Medicine, Houston, USA.
Sung Wook KangBaylor College of Medicine, Houston, USA.
Claire LeeBaylor College of Medicine, Houston, USA.
Priyanka RanchodBaylor College of Medicine, Houston, USA.
Bryan M BurtUniversity of California, Los Angeles, USA.
Hyun-Sung LeeBaylor College of Medicine, Houston, USA.
Christopher I AmosBaylor College of Medicine, Houston, USA. CIAmos@salud.unm.edu.

Funding

Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI DAVID R ROWLEY · 2007 to 2026
$73.9M
Translating Molecular and Clinical Data to Population Lung Cancer Risk AssessmentU19CA203654 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Christopher I. Amos · 2017 to 2026
$23.7M
Sequencing Familial Lung CancerR01CA243483 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Christopher I. Amos, DIPTASRI M MANDAL · 2023 to 2026
$4.2M
Intratumoral microbiota and immune predictors of response to immunotherapy in lung cancerR01CA285882 · NCI · BAYLOR COLLEGE OF MEDICINE · PI David C Christiani, Yanhong Liu · 2024 to 2026
$3.3M
Proteomic determinants of response to checkpoint blockade in malignant pleuralmesotheliomaR37CA248478 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Bryan Michael Burt · 2021 to 2026
$2.9M
Targeting the Mitochondria to Overcome Resistance to Immune Checkpoint Inhibition in Malignant Pleural MesotheliomaR37CA289419 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Robert Taylor Ripley · 2024 to 2026
$2.0M
Novel Biomarkers Predicting Blood Clots in Ovarian CancerR01CA275762 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Vahid Afshar-Kharghan, ANIL K SOOD · 2023 to 2026
$1.9M
NOVEL HUMORAL AND CELLULAR BIOMARKERS OF AUTOIMMUNE DISEASES CAUSED BY IMMUNOTHERAPYR21AI159379 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI LEE, HYUN-SUNG, REDONDO, MARIA JOSE · 2023 to 2024
$440k
Identifying germline pathogenic variants in familial lung cancer among African-AmericansR03CA282953 · NCI · BAYLOR COLLEGE OF MEDICINE · PI LIU, YANHONG · 2024 to 2025
$160k
Cancer Prevention and Research Institute of Texas RP200443Cancer Prevention and Research Institute of Texas RR170048French National Research Agency ANR-23-IAHU-007Helis Medical Research Foundation NCI-CA125123NCI NIH HHS P30 CA125123NCI NIH HHS R01 CA243483NCI NIH HHS R01 CA275762NCI NIH HHS R01 CA285882NCI NIH HHS R03 CA282953NCI NIH HHS R37 CA248478NCI NIH HHS R37 CA289419NCI NIH HHS U19 CA203654NIAID NIH HHS R21 AI159379NIH HHS U19CA203654, R01CA285, U24 2U24OH009077-15-00, R01CA275762, R01CA243483, R21AI159379, R37 CA248478, CA289419-01,882, R03CA282953,NIOSH CDC HHS U24 OH009077U.S. Department of Defense W81XWH-22-1-0657
6 · The paper itself

Abstract

backgroundLung adenocarcinoma (LUAD) has several histologically distinct subtypes that differ by a number of clinical features including patient survival. Molecular mechanisms underlying histological and clinical differences between subtypes remain poorly understood.

methodsWe conducted a comparative analyses of gene expression in acinar, lepidic, papillary and solid subtypes, as well as mucinous adenocarcinoma. We used a novel, more efficient approach to identify subtype-specific genes. We compared the mean gene expression level separately for tumors and adjacent normal tissue with pure or a highly represented (≥ 75%) subtype of interest to the mean expression in tumors where the subtype of interest was not present. We also performed tumor to adjacent normal tissue comparisons and identified genes differentially expressed between tumor and adjacent normal tissues for each subtype.

resultsThe number of subtype-specific genes varied from 1 for the acinar to 482 for the papillary subtype. Comparative analysis of gene expression in adjacent normal tissues also identified subtype-specific genes, 38 in total. Gene set enrichment analysis identified oxidative phosphorylation as a biological function associated with papillary, and immune response - with solid subtype. Using data on differential expression between tumor and adjacent normal tissue among the subtype-specific genes and existing evidence for association with lung carcinogenesis, we have identified several candidate subtype-specific driver genes. CONCLUSIO: n We identified subtype-specific genes, biological functions, and potential drivers of subtype-specific carcinogenesis for LUAD subtypes. The study showed importance of gene expression in adjacent normal tissue for subtype-specific tumorigenesis.

Indexed as

Adenocarcinoma of LungBiomarkers, TumorGene Expression Regulation, NeoplasticLung NeoplasmsGene Expression ProfilingHumansBiomarkers, TumorGene expressionLung adenocarcinoma (LUAD)Predominant subtypes

Identifiers

PMID40660181
PMCPMC12261662

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.